MA47494A - Nouvelles utilisations d'anticorps anti-sirpg - Google Patents
Nouvelles utilisations d'anticorps anti-sirpgInfo
- Publication number
- MA47494A MA47494A MA047494A MA47494A MA47494A MA 47494 A MA47494 A MA 47494A MA 047494 A MA047494 A MA 047494A MA 47494 A MA47494 A MA 47494A MA 47494 A MA47494 A MA 47494A
- Authority
- MA
- Morocco
- Prior art keywords
- new uses
- sirpg antibodies
- sirpg
- antibodies
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305184 | 2017-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47494A true MA47494A (fr) | 2019-12-25 |
Family
ID=58185462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047494A MA47494A (fr) | 2017-02-17 | 2018-02-15 | Nouvelles utilisations d'anticorps anti-sirpg |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190382483A1 (fr) |
EP (1) | EP3583128A1 (fr) |
JP (2) | JP7179743B2 (fr) |
KR (1) | KR20190117670A (fr) |
CN (1) | CN110300764A (fr) |
AU (1) | AU2018221774A1 (fr) |
BR (1) | BR112019016356A2 (fr) |
CA (1) | CA3051318A1 (fr) |
IL (1) | IL268731A (fr) |
MA (1) | MA47494A (fr) |
WO (1) | WO2018149938A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
JP2023503943A (ja) | 2019-11-27 | 2023-02-01 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための組み合わせ療法 |
TW202208431A (zh) * | 2020-05-08 | 2022-03-01 | 美商電子療法股份有限公司 | SIRPα及SIRPβ1抗體及其用途 |
KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
WO2022120286A1 (fr) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimères pour réduire l'interférence de médicaments qui se lient à cd47 dans des dosages sérologiques |
IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
TW202334224A (zh) * | 2021-11-10 | 2023-09-01 | 美商電子療法股份有限公司 | SIRPγ抗體及其用途 |
WO2023235754A1 (fr) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Polythérapies pour le traitement du carcinome urothélial |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB0607943D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Biomarkers for chronic transplant dysfunction |
ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
SG11201607143UA (en) * | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
WO2016118226A1 (fr) * | 2015-01-22 | 2016-07-28 | Sikorsky Aircraft Corporation | Conception de pale de rotor à faible bruit |
EP3285808A1 (fr) | 2015-04-21 | 2018-02-28 | Gilead Sciences, Inc. | Traitement de la maladie chronique du greffon contre l'hôte avec inhibiteurs syk |
CN107849143B (zh) | 2015-05-18 | 2021-12-10 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
WO2017178653A2 (fr) * | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques |
JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
-
2018
- 2018-02-15 BR BR112019016356A patent/BR112019016356A2/pt unknown
- 2018-02-15 WO PCT/EP2018/053831 patent/WO2018149938A1/fr unknown
- 2018-02-15 KR KR1020197027076A patent/KR20190117670A/ko not_active Application Discontinuation
- 2018-02-15 CA CA3051318A patent/CA3051318A1/fr active Pending
- 2018-02-15 MA MA047494A patent/MA47494A/fr unknown
- 2018-02-15 CN CN201880012199.6A patent/CN110300764A/zh active Pending
- 2018-02-15 EP EP18707306.9A patent/EP3583128A1/fr active Pending
- 2018-02-15 AU AU2018221774A patent/AU2018221774A1/en active Pending
- 2018-02-15 JP JP2019544888A patent/JP7179743B2/ja active Active
- 2018-02-15 US US16/485,697 patent/US20190382483A1/en not_active Abandoned
-
2019
- 2019-08-15 IL IL26873119A patent/IL268731A/en unknown
-
2022
- 2022-01-09 US US17/571,499 patent/US20220242951A1/en active Pending
- 2022-11-15 JP JP2022182731A patent/JP2023010810A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020510643A (ja) | 2020-04-09 |
CN110300764A (zh) | 2019-10-01 |
IL268731A (en) | 2019-10-31 |
JP2023010810A (ja) | 2023-01-20 |
KR20190117670A (ko) | 2019-10-16 |
AU2018221774A1 (en) | 2019-08-08 |
WO2018149938A1 (fr) | 2018-08-23 |
BR112019016356A2 (pt) | 2020-04-07 |
EP3583128A1 (fr) | 2019-12-25 |
US20190382483A1 (en) | 2019-12-19 |
JP7179743B2 (ja) | 2022-11-29 |
CA3051318A1 (fr) | 2018-08-23 |
US20220242951A1 (en) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
MA49043A (fr) | Formulation stable d'anticorps | |
MA47694A (fr) | Anticorps anti-tigit | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA53434A (fr) | Anticorps anti-tigit | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
MA51134A (fr) | Anticorps anti-alpha-synucléine | |
MA52152A (fr) | Anticorps |